Gliead Sciences Inc.
Gilead Sciences Inc. (IW 500/111)
reported $10 billion in revenue for 2012, a 16% increase from 2011.
Last week the company announced it submitted a New Drug Application to the U.S. FDA for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of indolent non-Hodgkin’s lymphoma.
“Gilead is committed to advancing a pipeline of novel cancer therapies that have the potential to improve the lives of patients,” said John C. Martin, PhD, Chairman and Chief Executive Officer of Gilead Sciences.
“Based on the rate and duration of response observed to date in this highly refractory iNHL patient population, we believe idelalisib could become an important new therapy for patients who have limited treatment options.”